Sumatriptan
FDA-approved product (spray, nasal), marketed as Imitrex, Sumatriptan, Tosymra and 8 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Migraine disorder
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Selective serotonin (5ht1) agonists
- FDA pharmacologic class
- Serotonin-1b and Serotonin-1d Receptor Agonist FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA31.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli27.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae24.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Sumatriptan with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Abiraterone AcetateExisting use: Cancer, Metastatic prostate cancer, Neoplasm and 3 more62.1% AI-predicted activityagainst MRSA50+ registered studies
- TicagrelorExisting use: Acute coronary syndrome, Acute myocardial infarction, Coronary artery disease and 6 more62.1% AI-predicted activityagainst MRSA50+ registered studies
- Edoxaban TosylateExisting use: Atrial fibrillation, Deep vein thrombosis, Pulmonary embolism and 3 more62.1% AI-predicted activityagainst MRSA22 registered studies
- CrizotinibExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma62.0% AI-predicted activityagainst MRSA50+ registered studies
- Montelukast SodiumExisting use: Airway obstruction, Allergic rhinitis, Asthma and 2 more62.0% AI-predicted activityagainst MRSA50+ registered studies
- GrazoprevirExisting use: Chronic hepatitis C virus infection61.9% AI-predicted activityagainst MRSA50+ registered studies
- Octreotide AcetateExisting use: Acromegaly, Carcinoid tumor, Metastasis and 1 more61.7% AI-predicted activityagainst MRSA50+ registered studies
- CyclosporineExisting use: Conjunctivitis, Corneal disease, Eye disease and 6 more61.7% AI-predicted activityagainst MRSA50+ registered studies
- AnidulafunginExisting use: Candidemia, Candidiasis, Peritonitis61.6% AI-predicted activityagainst MRSA43 registered studies
- Triptorelin PamoateExisting use: Central precocious puberty, Metastatic prostate cancer, Neoplasm and 3 more61.6% AI-predicted activityagainst MRSA50+ registered studies
- Vinblastine SulfateExisting use: Classic Hodgkin lymphoma, Fungal infectious disease, Hodgkins lymphoma and 3 more61.5% AI-predicted activityagainst MRSA50+ registered studies
- Lenacapavir SodiumExisting use: HIV infection, HIV-1 infection, Viral disease61.5% AI-predicted activityagainst MRSANo documented evidence found
Registered studies
A registration describes a study; it does not establish a positive result.
To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migrane Headaches
NCT00434083 · start 2004-07
Registered record
- Registry ID
- NCT00434083
- Conditions
- Migraine Headaches
- Interventions
- sumatriptan; naproxen sodium
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2004-07
- Completion
- 2005-01
- Enrolment
- 1,200
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMigraine HeadachesInterventionsumatriptan; naproxen sodiumPhasePhase 3Registry statusCompletedSumatriptan Succinate 100 mg Tablets Under Fasting Conditions
NCT00847405 · start 2003-03
Registered record
- Registry ID
- NCT00847405
- Conditions
- Healthy
- Interventions
- Sumatriptan Succinate; Imitrex®
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2003-03
- Completion
- 2003-03
- Enrolment
- 28
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionSumatriptan Succinate; Imitrex®PhasePhase 1Registry statusCompletedSumatriptan and Naratriptan Pregnancy Registry
NCT01059604 · start 2001-12
Registered record
- Registry ID
- NCT01059604
- Conditions
- Migraine Disorders
- Interventions
- Sumatriptan; Naratriptan; Sumatriptan-naproxen combination
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2001-12
- Completion
- 2013-04
- Enrolment
- 868
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMigraine DisordersInterventionSumatriptan; Naratriptan; Sumatriptan-naproxen combinationPhaseNot recordedRegistry statusCompletedDrug Use Investigation for IMIGRAN Tablet
NCT01376141 · start 2001-09
Registered record
- Registry ID
- NCT01376141
- Conditions
- Migraine Disorders
- Interventions
- Sumatriptan
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2001-09
- Completion
- 2005-11
- Enrolment
- 3,571
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMigraine DisordersInterventionSumatriptanPhaseNot recordedRegistry statusCompletedMK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)
NCT00897104 · start 1995-08
Registered record
- Registry ID
- NCT00897104
- Conditions
- Migraine Headache
- Interventions
- rizatriptan benzoate (MK0462); Comparator: sumatriptan; Comparator: Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 1995-08
- Completion
- 1996-09
- Enrolment
- 933
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMigraine HeadacheInterventionrizatriptan benzoate (MK0462); Comparator: sumatriptan; Comparator: PlaceboPhasePhase 3Registry statusCompleted